Clinical trial
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
NCT00413101 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00413101 |
|---|---|
| Title | A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease. |
| Official title | An Open-Label Study to Investigate Improvement in Heart Function After Complete Anemia Correction With NeoRecormon in Patients With End-Stage Renal Disease Already Receiving Sub-Optimal Doses of NeoRecormon |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | epoetin beta [NeoRecormon] |
| Enrollment | 50 |
| Completion | Mar 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | May 14, 2009 |
| Countries | Serbia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: